Mohlo by se vám také líbit

Více informací o knize Drugs for HER-2-positive Breast Cancer

• Parametry knihy
• Anotace
• Oblíbené z jiného soudku

Nákupem získáte 467 bodů

Anotace knihy

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Parametry knihy

Zařazení knihy Knihy v angličtině Medicine Clinical & internal medicine Diseases & disorders

• Plný název: Drugs for HER-2-positive Breast Cancer
• Autor: Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch
• Jazyk: Angličtina
• Vazba: Pevná
• Počet stran: 110
• EAN: 9783034600934
• ISBN: 3034600933
• ID: 01438610
• Nakladatelství: Birkhauser Verlag AG
• Hmotnost: 384 g
• Rozměry: 244 × 164 × 14 mm
• Datum vydání: 07. January 2011

Oblíbené z jiného soudku

---

---

---